Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Candel Therapeutics (CADL) Gains from Sales and Divestitures (2023 - 2025)

Candel Therapeutics' Gains from Sales and Divestitures history spans 1 years, with the latest figure at $306185.0 for Q4 2023.

On a quarterly basis, Gains from Sales and Divestitures changed N/A to $306185.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $306185.0, a N/A change, with the full-year FY2023 number at $306185.0, changed N/A from a year prior.
Gains from Sales and Divestitures hit $306185.0 in Q4 2023 for Candel Therapeutics.
Over the last five years, Gains from Sales and Divestitures for CADL hit a ceiling of $306185.0 in Q4 2023 and a floor of $306185.0 in Q4 2023.